journal
MENU ▼
Read by QxMD icon Read
search

European Heart Journal. Cardiovascular Pharmacotherapy

journal
https://www.readbyqxmd.com/read/30423165/outcomes-associated-with-non-recommended-dosing-of-rivaroxaban-results-from-the-xantus-study
#1
Pierre Amarenco, Sylvia Haas, Susanne Hess, Paulus Kirchhof, Marc Lambelet, Miriam Bach, Alexander Gg Turpie, A John Camm
Aims: In Europe, the approved rivaroxaban dose for stroke prevention in patients with atrial fibrillation is 20 mg once daily (od), with 15 mg od recommended in patients with creatinine clearance [CrCl] 15-49 mL/min. Non-recommended doses are prescribed in real-world practice. This analysis of the XANTUS study assessed outcomes associated with non-recommended dosing and patient characteristics that may have impacted dose choice. Methods and results: Baseline characteristics and 1-year outcomes were compared in 4464/6784 patients with known CrCl, receiving recommended or non-recommended rivaroxaban doses; 3608 (80...
November 13, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30398614/long-term-antiarrhythmic-drug-treatment-after-atrial-fibrillation-ablation-does-too-obstinate-rhythm-control-strategy-bring-serious-risk-of-proarrhythmia-to-ablated-patients
#2
Renato De Vecchis
No abstract text is available yet for this article.
November 6, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30339228/corrigendum
#3
(no author information available yet)
No abstract text is available yet for this article.
October 17, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30289484/dropping-aspirin-in-patients-with-atrial-fibrillation-undergoing-percutaneous-coronary-intervention-a-jump-with-a-weak-parachute
#4
Mattia Galli, Felicita Andreotti, Gianluigi Savarese, Domenico D'Amario, Rocco Vergallo, Roberta Della Bona, Leonardo Calò, Italo Porto, Filippo Crea
No abstract text is available yet for this article.
October 5, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30289465/corrigendum
#5
(no author information available yet)
No abstract text is available yet for this article.
October 4, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30285099/neoatherosclerosis-after-drug-eluting-stent-implantation-a-novel-clinical-and-therapeutic-challenge
#6
Josip A Borovac, Domenico D'Amario, Rocco Vergallo, Italo Porto, Antonio Bisignani, Mattia Galli, Gianmarco Annibali, Rocco A Montone, Antonio Maria Leone, Giampaolo Niccoli, Filippo Crea
The recognition that obstructive disease of the epicardial coronary arteries, causing ischemic heart disease, can be treated with a percutaneous coronary intervention (PCI) has been a major discovery in cardiology in the last 40 years contributing, in particular, to the reduction of mortality associated to acute myocardial infarction (AMI). However, even in the era of drug-eluting stent (DES) implantation, a sizable proportion of patients who undergo PCI may develop late or very late post-implantation complications, that occur in the form of restenosis, neoatherosclerosis and/or in-stent thrombosis...
October 4, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30247574/baseline-low-density-lipoprotein-cholesterol-to-predict-the-extent-of-cardiovascular-benefit-from-lipid-lowering-therapies-a-review
#7
Eliano P Navarese, Felicita Andreotti, Paolo Raggi, Michalina Kolodziejczak, Antonino Buffon, Kevin Bliden, Udaya Tantry, Jacek Kubica, Gennaro Sardella, Alexander Lauten, Stefan Agewall, Paul A Gurbel, Marc A Brouwer
Importance: Lipid-lowering therapies have been shown to improve cardiovascular outcome in a wide range of patients. The current guidelines recommend a graded approach to reduction in low-density lipoprotein cholesterol (LDL-C) proportional to the patient's risk, with the goal of achieving either a certain magnitude of reduction or a specific threshold of final LDL-C. Observations: Recent findings from a meta-analysis of numerous randomized trials suggest that more attention should be given to the baseline LDL-C of an individual patient...
September 21, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30192939/mortality-and-adverse-events-with-brand-and-generic-clopidogrel-in-the-food-and-drug-administration-adverse-event-reporting-system-faers
#8
Victor L Serebruany, Trygve S Hall, Dan Atar, Stefan Agewall, Moo Hyun Kim, Bernard Geudelin, Nikita Lomakin, Thomas A Marciniak
Background and Aim: Clopidogrel is commonly used even after expiring patents. The brand clopidogel (BC) was dealt by single company, while numerous manufacturers produce generic clopidogrel (GC). There are no convincing data to compare the safety of different formulations. Therefore, the data yielded from international, uniform, government-mandated registries may be useful. Methods and Results: We assessed primary causative adverse events (PCAE) after BC and GC in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)...
September 6, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30192930/effect-of-oral-%C3%AE-blocker-treatment-on-mortality-in-contemporary-post-myocardial-infarction-patients
#9
Magnus Dahl Aarvik, Irene Sandven, Tatendashe B Dondo, Chris P Gale, Vidar Ruddox, John Munkhaugen, Dan Atar, Jan Erik Otterstad
Aims: Guidelines concerning β-blocker treatment following acute myocardial infarction (AMI) are based on studies undertaken before the implementation of reperfusion and secondary prevention therapies. We aimed to estimate the effect of oral β-blockers on mortality in contemporary post-AMI patients with low prevalence of heart failure (HF) and/or reduced left ventricular ejection fraction (LVEF). Methods and Results: A random effects model was used to synthetize results of 16 observational studies published between January 1st 2000 and October 30th 2017...
September 6, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30165588/esc-council-on-hypertension-position-document-on-the-management-of-hypertensive-emergencies
#10
Bert-Jan H van den Born, Gregory Y H Lip, Jana Brguljan-Hitij, Antoine Cremer, Julian Segura, Enrique Morales, Felix Mahfoud, Fouad Amraoui, Alexandre Persu, Thomas Kahan, Enrico Agabiti Rosei, Giovanni de Simone, Philippe Gosse, Bryan Williams
Hypertensive emergencies are those situations where very high blood pressure (BP) values are associated with acute organ damage, and therefore, require immediate, but careful, BP reduction. The type of acute organ damage is the principal determinant of: (i) the drug of choice, (ii) the target BP, and (iii) the timeframe in which BP should be lowered. Key target organs are the heart, retina, brain, kidneys, and large arteries. Patients who lack acute hypertension-mediated end organ damage do not have a hypertensive emergency and can usually be treated with oral BP-lowering agents and usually discharged after a brief period of observation...
August 25, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30295788/beware-of-early-drug-intolerance-in-secondary-prevention-of-cardiovascular-disease
#11
Raul D Santos
No abstract text is available yet for this article.
October 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30113628/critical-appraisal-of-the-compass-trial
#12
Alexander Niessner, Stefan Agewall
No abstract text is available yet for this article.
October 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30060063/development-of-triglyceride-lowering-drugs-to-address-residual-cardiovascular-risk-strategic-and-clinical-considerations
#13
Jonas Hallén, Nadarajah Sreeharan
The prevalence of hypertriglyceridaemia is high and growing in several parts of the world. Hypertriglyceridaemia has a well-defined association with the risk of atherosclerotic cardiovascular (CV) disease and triglycerides represent a potential target for drugs aimed at mitigating CV risk. So far, no triglyceride-lowering pharmacological strategy has succeeded in conclusively showing the ability to modify clinical outcomes. This article discusses strategic and clinical aspects of development of triglyceride-lowering drugs to address CV disease...
October 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30101278/influence-of-intravenous-fentanyl-compared-with-morphine-on-ticagrelor-absorption-and-platelet-inhibition-in-patients-with-st-segment-elevation-myocardial-infarction-undergoing-primary-percutaneous-coronary-intervention-rationale-and-design-of-the-perseus-randomized
#14
Sophie Degrauwe, Marco Roffi, Nathalie Lauriers, Olivier Muller, Pier Giorgio Masci, Marco Valgimigli, Juan F Iglesias
Background and aims: Recent evidence demonstrates that intravenous morphine significantly reduces absorption and delays onset of action of oral P2Y12 receptor inhibitors in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). We aimed to assess the influence of intravenous fentanyl compared with morphine on pharmacokinetics (PK) and pharmacodynamics (PD) of ticagrelor and its active metabolite (AR-C124910XX) in patients undergoing pPCI for STEMI...
August 8, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30099530/reasons-for-disparity-in-statin-adherence-rates-between-clinical-trials-and-real-world-observations-a-review
#15
Alexander Vonbank, Heinz Drexel, Stefan Agewall, Basil S Lewis, Joern F Dopheide, Keld Kjeldsen, Claudio Ceconi, Gianluigi Savarese, Giuseppe Rosano, Sven Wassmann, Alexander Niessner, Thomas Andersen Schmidt, Christoph H Saely, Iris Baumgartner, Juan Tamargo
With statins, the reported rate of adverse events differs widely between randomized clinical trials (RCTs) and observations in clinical practice, the rates being 1-2% in RCTs versus 10-20% in the so-called real world. One possible explanation is the claim that RCTs mostly use a run-in period with a statin. This would exclude intolerant patients from being included into RCTs and therefore favor a bias towards lower rates of intolerance.We here review data from RCTs with more than 1000 participants with and without a run-in period, which were included in the Cholesterol Treatment Trialists collaboration (CTTC)...
August 7, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30084902/trends-in-cardiovascular-and-bleeding-outcomes-in-acute-coronary-syndrome-patients-treated-with-or-without-proton-pump-inhibitors-during-the-introduction-of-novel-p2y12-inhibitors-a-five-year-experience-from-a-single-centre-observational-registry
#16
N P G Hoedemaker, P Damman, J P Ottervanger, J H E Dambrink, A T M Gosselink, E Kedhi, E Kolkman, R J de Winter, A W J van 't Hof
Objective: Proton-pump inhibitors (PPI) are commonly prescribed in acute coronary syndrome (ACS) patients on antiplatelet therapy. We studied PPI prescription in ACS patients in the era of novel P2Y12 inhibitors and assessed the association between PPI use and clinical outcomes. Methods: Between 2010 and 2014, we included all consecutive ACS patients admitted to a Dutch tertiary hospital. The main outcome was PPI prescription at discharge. Additionally, we present 1-year mortality and 30-day cardiovascular and bleeding outcomes...
August 2, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30084983/head-to-head-comparison-between-the-non-vitamin-k-antagonist-oral-anticoagulants-for-treatment-of-venous-thrombo-embolism-do-we-really-need-it
#17
Dragos Vinereanu
No abstract text is available yet for this article.
July 31, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30052825/a-randomized-double-blind-placebo-controlled-trial-assessing-the-efficacy-of-s66913-in-patients-with-paroxysmal-atrial-fibrillation
#18
John A Camm, Paul Dorian, Stefan H Hohnloser, Peter R Kowey, Benoît Tyl, Yongbin Ni, Victoria Vandzhura, Pierre Maison-Blanche, Mirko de Mellis, Prashanthan Sanders
Background: Anti-arrhythmic drugs (AAD) for the treatment of atrial fibrillation (AF) are associated with limited efficacy and adverse effects. Inhibition of the atrial current IKur, absent from the ventricle, is expected to be antiarrhythmic, without adverse cardiac effects, particularly ventricular pro-arrhythmic effects. Methods: A randomized clinical trial in symptomatic paroxysmal AF patients being considered for ablation. The primary endpoint was AF burden (AFB) as measured by insertable continuous monitoring (ICM) devices...
July 23, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30052822/differences-in-the-risk-of-stroke-bleeding-events-and-mortality-between-female-and-male-patients-with-atrial-fibrillation-during-warfarin-therapy
#19
Tero Penttilä, Mika Lehto, Jussi Niiranen, Juha Mehtälä, Houssem Khanfir, Riitta Lassila, Pekka Raatikainen
Aims: Females with atrial fibrillation (AF) have been suggested to carry a higher risk for thromboembolic events than males. We compared the residual risk of stroke, bleeding events, and cardiovascular and all-cause mortality among female and male AF patients taking warfarin. Methods and results: Data from several nationwide registries and laboratory databases were linked with the civil registration number of the patients. A total of 54568 patients with data on the quality of warfarin treatment (time in therapeutic range) 60 days prior to the events were included (TTR60)...
July 21, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30020424/effectiveness-and-safety-of-rivaroxaban-versus-warfarin-in-nonvalvular-atrial-fibrillation-patients-with-a-non-sex-related-cha2ds2-vasc-score-of-1
#20
Craig I Coleman, Alexander G G Turpie, Thomas J Bunz, Daniel Eriksson, Nitesh A Sood, William L Baker
Aims: To compare the effectiveness and safety of standard dose rivaroxaban (20 mg once daily) and warfarin in nonvalvular atrial fibrillation (NVAF) patients with a non-sex-related CHA2DS2-VASc score of 1. Methods and Results: Analysis of United States Truven MarketScan claims from 11/2011-12/2016 for anticoagulant-naïve NVAF patients with a single non-sex-related stroke risk factor assigned 1-point in the CHA2DS2-VASc score and ≥12-months of continuous medical/prescription insurance coverage prior to the qualifying oral anticoagulant dispensing...
July 17, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
journal
journal
53372
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"